Movano health's proprietary chip and prototype achieves accuracy commensurate with the fda's requirements for blood pressure monitoring

Leveraging the company's 4 x 6.7 mm system-on-a-chip (soc), the clinical study results are a significant step forward in commercializing a cuffless, radio frequency (rf)-enabled blood pressure device pleasanton, calif. , oct. 31, 2023 /prnewswire/ -- movano health (nasdaq: move), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of the evie ring, today announced the results of its institutional review board (irb)-approved blood pressure clinical study.
MOVE Ratings Summary
MOVE Quant Ranking